CTMX - CytomX Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue71,62315,0437,712
Cost of Revenue---
Gross Profit71,62315,0437,712
Operating Expenses
Research Development92,27754,75528,357
Selling General and Administrative25,60519,87412,558
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-46,259-59,586-33,203
Income from Continuing Operations
Total Other Income/Expenses Net2,647667-429
Earnings Before Interest and Taxes-43,612-58,919-33,632
Interest Expense--1,732
Income Before Tax-43,612-58,919-35,364
Income Tax Expense-513-1910
Minority Interest---
Net Income From Continuing Ops-43,099-58,900-35,374
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-43,099-58,900-35,374
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-43,099-58,900-42,079